Daily Bio News Summary — 2026-07-30: Capricor DMD rejection caps a heavy FDA week

Today’s harvest brought in 44 fresh articles across four sources (BioSpace, Endpoints News, STAT News, FDA Newsroom). All passed the 30-day freshness filter and were screened for political/op-ed framing per Rule 7; STAT Plus paywalled pieces were excluded at the title-prefix level. Several narratives cluster today — Capricor and Replimune both face FDA questions about efficacy, J&J is building out its in vivo CAR-T position through Sail, and Sanofi is simultaneously resetting R&D strategy under its new CEO. Below are the dominant themes, with each cluster attributed to its source.

FDA activity — Capricor and Replimune bear the brunt

Two clinical-regulatory stories dominate the FDA beat today. Capricor’s deramiocel for Duchenne muscular dystrophy was rejected by an FDA advisory committee in a vote the source described as “chaotic” (BioSpace, 2026-07-29); the FDA staff also publicly disputed Capricor’s claims of Phase 3 success for the cell therapy (BioSpace, 2026-07-27), and Endpoints reported an “Updated: FDA adcomm votes down Capricor’s DMD therapy over efficacy” piece the same week (Endpoints News, 2026-07-29). On the same FDA staff briefing track, Replimune’s pivotal melanoma trial for RP1 was reported to have failed to prove RP1 works, pushing the stock down (Endpoints News, 2026-07-28); an FDA reminder that re-evaluations do not equal new conclusions explicitly invoked both Capricor and Replimune as cautionary examples (Endpoints News, 2026-07-28).

Separately, the FDA formally licensed the first-ever freeze-dried plasma product in the United States on 2026-07-29 (FDA Newsroom, 2026-07-29) — the lone FDA Newsroom item in today’s batch.

M&A and dealmaking — J&J anchors an in vivo CAR-T play

Two J&J-Sail stories top the M&A cluster. J&J secured the right to take the helm in an up-to-$925M Sail CAR-T pact (BioSpace, 2026-07-30), and a separate Endpoints piece reported J&J lining up a $2.58B option to acquire Sail (Endpoints News, 2026-07-30) — together sketching out a Flagship Pioneering in vivo CAR-T consolidation play. AtaiBeckley attracted co-development and royalty offers before signing its $2.8B Lilly deal (Endpoints News, 2026-07-30). Pfizer posted a Phase 3 win for Litfulo in vitiligo, and Braveheart/Attovia eye IPOs of $275M and $182M respectively (Endpoints News, 2026-07-30). Ipsen said it has ‘firepower’ for more deals with a €2B war chest (Endpoints News, 2026-07-30), and Regeneron’s “aversion to M&A” was questioned as its bumper Q2 builds a war chest (BioSpace, 2026-07-30).

Public-company earnings — BMS, Regeneron, UCB, Alnylam, Biogen

Q2 earnings flow into the picture across multiple tickers. BMS’ “big beat” was clouded by Cobenfy and heart-disease data delays (BioSpace, 2026-07-30); Regeneron revenue was up 17% on Dupixent (per Endpoints coverage paraphrased above), and UCB beat its sales forecast but the stock fell on guidance concerns (Endpoints News, 2026-07-30). Alnylam cut Amvuttra sales guidance as demand shifted, hurting the stock (Endpoints News, 2026-07-30), and Biogen shifted M&A strategy as its Apellis acquisition pushes revenue above analyst expectations (BioSpace, 2026-07-29); Leqembi recorded its best quarter since launch as Biogen raised underlying guidance (Endpoints News, 2026-07-29). Daiichi’s pipeline fell behind rivals as cash flow neared peak, per analysts (BioSpace, 2026-07-30).

Sanofi — new CEO, R&D reset, and a €1B write-off

Three Sanofi items today form a coherent strategy narrative. The new Sanofi CEO wants a more “realistic view” of Phase 3 go/no-go decisions (BioSpace, 2026-07-30); Garijo’s plan to revamp Sanofi envisions an R&D cleanup, more M&A and a China push (Endpoints News, 2026-07-30); and Sanofi recorded a €1B+ write-off, ending work on two immunology assets (Endpoints News, 2026-07-30).

Pipeline, platforms, and biotechs

Kyverna tapped ElevateBio to secure commercial supply of its autoimmune CAR-T therapy (BioSpace, 2026-07-29). Incyte cut an early-stage cancer drug to focus on next-gen programs (BioSpace, 2026-07-29). Private biotechs Caldera and Vidya raised $478M collectively via reverse go-public mergers (BioSpace, 2026-07-29). Daiichi’s pipeline framing was covered separately above. The FDA also reminded investors about re-evaluations (see FDA cluster). Novo Nordisk was ordered to face CagriSema fraud claims from shareholders in a New Jersey court (BioSpace, 2026-07-29). Gerresheimer divested two businesses worth €1.5B, with Resilience and Lilly boosting injectable pen capacity (Endpoints News, 2026-07-30).

Careers, hiring, and market commentary

Five BioSpace items are careers-focused today. “New funding, new jobs: 4 biotechs hiring after series B raises” (BioSpace, 2026-07-30) and “Not-so-special delivery: When biopharmas fumble layoff news” (BioSpace, 2026-07-30) capture the post-funding labor market. “Do you need oncology experience to land an oncology job?” (BioSpace, 2026-07-29) and “7 companies hiring in New York now” (BioSpace, 2026-07-29) round out the regional hiring slate. “Standing out, not blending in: how AI tools can drive impact during job searches” (BioSpace, 2026-07-15) is an evergreen-style piece. “Biotechs bring big launches and pharma rivalries into Q2 earnings period” (BioSpace, 2026-07-29) and “Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more” (BioSpace, 2026-07-29) sit at the intersection of earnings, regulatory, and personnel news.

Global health, manufacturing, and STAT free reads

The State Department released $600M for the global health group Gavi (Endpoints News, 2026-07-29). NYU’s Neil Vasan departed as acting chair of FDA’s cancer drug advisory panel (Endpoints News, 2026-07-29). From sequence to scale: gene editing’s new era in biologics manufacturing (BioSpace, 2026-07-10) and Nordic biotech’s next act: from fragmentation to global force (BioSpace, 2026-07-23) provide industry-state commentary.

Four STAT News free articles round out today’s list: “Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases” (STAT News, 2026-07-30); “Is it safe to drink Red Bull and alcohol? Questionable research tied to energy drink giant has shaped policy” (STAT News, 2026-07-30); “NSF testing new Ph.D. model giving trainees academic and industry experience” (STAT News, 2026-07-29); and “Ebola outbreak nears milestone, while a vaccine remains months away” (STAT News, 2026-07-30).

What this batch is NOT telling us

Today’s harvest is notably light on AI-bio coverage — only the AI-tools-for-job-searches piece qualifies, and none of the headline AI-bio companies (Insilico, Isomorphic, Recursion, Generate) appear. IPO and reverse-merger coverage is also light beyond the Braveheart/Attovia/AtaiBeckley/Caldera/Vidya cluster. Endpoints’ planned FDA preview coverage of Capricor and Replimune appears in two separate pieces but no new clinical readouts from Phase 3 studies (other than the Litfulo Phase 3 win) made today’s batch. STAT Plus content was filtered out at the title-prefix level — about half of STAT’s homepage fell to that filter.

Reading order for limited-time readers

1. “FDA staff say Replimune’s pivotal melanoma trial failed to prove RP1 works, pushing down stock” (Endpoints News, 2026-07-28) — the single highest-impact regulatory miss of the week.
2. “J&J lines up $2.58B option to buy Sail, Flagship’s in vivo CAR-T biotech” (Endpoints News, 2026-07-30) — sets the in vivo CAR-T consolidation frame.
3. “Sanofi records €1B+ write-off, ends work on two immunology assets” (Endpoints News, 2026-07-30) — concrete signal of Sanofi’s R&D reset under the new CEO.
4. “FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting” (BioSpace, 2026-07-29) — primary adcomm miss, with FDA staff later disputing Capricor’s efficacy claims.
5. “Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock” (Endpoints News, 2026-07-30) — the largest single-day stock-mover in today’s batch.

How to read the underlying articles

Every news item in this synthesis is backed by a markdown file in src/content/news/ whose sourceUrl field links to the original story. The corresponding sourceName field tells you which publication reported it. Articles written today include the primary company as companyId where one was identifiable from the headline; mega-cap pharma references (BMS, J&J, Pfizer, Sanofi, Lilly, Novo Nordisk) still get companyId set to keep cross-links working, but their company JSONs were already present in the directory and were not regenerated today. New company JSONs were created today for sail-biomedicines.json and caldera-therapeutics.json (both private biotechs, no active jobs in jobscraper.db so both use the “See all open roles” placeholder).

All 44 items, by source

FDA Newsroom (1)

• July 29, 2026 - FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S. (FDA Newsroom, 2026-07-29)

STAT News (4)

• Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases (STAT News, 2026-07-30)
• Is it safe to drink Red Bull and alcohol? Questionable research tied to energy drink giant has shaped policy (STAT News, 2026-07-30)
• NSF testing new Ph.D. model giving trainees academic and industry experience (STAT News, 2026-07-29)
• Ebola outbreak nears milestone, while a vaccine remains months away (STAT News, 2026-07-30)

BioSpace (23)

• FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting (BioSpace, 2026-07-29)
• BMS’ ‘big beat’ clouded by Cobenfy, heart-disease data delays (BioSpace, 2026-07-30)
• Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest (BioSpace, 2026-07-30)
• Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts (BioSpace, 2026-07-30)
• J&J secures right to take the helm in up to $925M Sail CAR-T pact (BioSpace, 2026-07-30)
• Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions (BioSpace, 2026-07-30)
• Life after the lead asset: Advancing an early-stage pipeline (BioSpace, 2026-07-30)
• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store (BioSpace, 2026-07-30)
• Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers (BioSpace, 2026-07-29)
• Biotechs bring big launches and pharma rivalries into Q2 earnings period (BioSpace, 2026-07-29)
• Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more (BioSpace, 2026-07-29)
• Nordic biotech’s next act: From fragmentation to global force (BioSpace, 2026-07-23)
• New funding, new jobs: 4 biotechs hiring after series B raises (BioSpace, 2026-07-30)
• Not-so-special delivery: When biopharmas fumble layoff news (BioSpace, 2026-07-30)
• Do you need oncology experience to land an oncology job? (BioSpace, 2026-07-29)
• 7 companies hiring in New York now (BioSpace, 2026-07-29)
• Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations (BioSpace, 2026-07-29)
• Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy (BioSpace, 2026-07-29)
• Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court (BioSpace, 2026-07-29)
• Standing out, not blending in: how AI tools can drive impact during job searches (BioSpace, 2026-07-15)
• UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy (BioSpace, 2026-07-27)
• Incyte cuts early-stage cancer drug to focus on next-gen programs (BioSpace, 2026-07-29)
• From sequence to scale: Gene editing’s new era in biologics manufacturing (BioSpace, 2026-07-10)

Endpoints News (16)

• Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock (Endpoints News, 2026-07-30)
• Garijo’s plan to revamp Sanofi: an R&D cleanup, more M&A and a China push (Endpoints News, 2026-07-30)
• Updated: FDA adcomm votes down Capricor’s DMD therapy over efficacy (Endpoints News, 2026-07-29)
• UCB beats sales forecast, but stock falls on concern guidance may be too rosy (Endpoints News, 2026-07-30)
• Pfizer’s Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M (Endpoints News, 2026-07-30)
• AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal (Endpoints News, 2026-07-30)
• Ipsen has ‘firepower’ for more deals with €2B war chest (Endpoints News, 2026-07-30)
• J&J lines up $2.58B option to buy Sail, Flagship’s in vivo CAR-T biotech (Endpoints News, 2026-07-30)
• Sanofi records €1B+ write-off, ends work on two immunology assets (Endpoints News, 2026-07-30)
• State Department releases $600M for global health group Gavi (Endpoints News, 2026-07-29)
• NYU’s Neil Vasan departs as acting chair of FDA’s cancer drug advisory panel (Endpoints News, 2026-07-29)
• Leqembi records best quarter since launch as Biogen raises underlying guidance (Endpoints News, 2026-07-29)
• FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune (Endpoints News, 2026-07-28)
• J&J proposes $5.5B talc settlement (Endpoints News, 2026-07-28)
• FDA staff say Replimune’s pivotal melanoma trial failed to prove RP1 works, pushing down stock (Endpoints News, 2026-07-28)
• Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity (Endpoints News, 2026-07-30)